Multiple Sclerosis News Blog

Read Detailed Profiles of Key Compounds in Development for Use in Multiple Sclerosis, With Forecasts of Drug Revenues To 2016

DUBLIN, Ireland--(BUSINESS WIRE)--May 4, 2007 - Research and Markets (http://www.researchandmarkets.com/reports/c55998) has announced the addition of Pipeline Insight: Multiple Sclerosis - The Oral Revolution to their offering.

The launch of five novel orally administered disease-modifiers is set to revolutionize the multiple sclerosis (MS) market, which will more than double in value across the seven major markets from 2006 to reach $10.7 billion in 2016.

Scope of this title:

Analysis of patient potential, unmet needs and clinical trial design in multiple sclerosis. Overview of drugs in late- and early-stage clinical development; with analysis of key companies involved in the R&D pipeline. Detailed profiles of key compounds in development for use in multiple sclerosis, with forecasts of drug revenues to 2016. Discussion of Biogen Idecs and Tevas strategies and insight from key industry opinion leaders

Highlights of this title:

There is a significant need for a MS treatment with superior efficacy to current therapies with a less invasive and time-consuming route of administration. Novartis oral Fingolimod (FTY720) goes some way to meet these needs and represents the most highly anticipated pipeline drug since the initial launch of Tysabri in 2004. Amid an increasingly competitive first-line therapy market, the author believes prospective players can gain competitive edge (and healthcare payer acceptance) by defining clear clinical differentiators in their trials. Head-to-head studies with a suitable comparator or showing benefit of add-on therapy represent two possible strategies. Biogen Idecs Rituxan (rituximab) and BioMS MBP-8298 are targeting the prevalent yet largely underserved primary progressive MS (PPMS) and secondary progressive MS (SPMS) indications. The author predicts that if Rituxan and MBP-8298 launch, then strong uptake can be expected.

Reasons to order your copy:

Understand unmet needs in the multiple sclerosis market based on key opinion leader comments Benchmark key late-stage disease-modifying multiple sclerosis compounds against current market leaders Assess the global (US, Japan, five major EU) sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential

Chapter Outline:

Chapter 1. Executive summary

Chapter 2. Multiple sclerosis pipeline overview and dynamics

Chapter 3. Multiple sclerosis disease overview and market potential

Chapter 4. R&D approach

Chapter 5. Cytokine late-stage drug analysis & forecasts

Chapter 6. Immunomodulator late-stage drug analysis and forecasts

Chapter 7. Myelin basic protein modulator late-stage drug analysis and forecasts

Chapter 8. Dehydrogenase inhibitor late-stage drug analysis and forecasts

Chapter 9. Human immunoglobulin late-stage drug analysis and forecasts

Chapter 10. Therapeutic vaccine late-stage drug analysis and forecasts

Chapter 11. Other late-stage drug analysis and forecasts